Cancer drug trials often at risk of bias, study finds
Randomized controlled studies are not all alike, as researchers determined about half of pivotal studies supporting recent cancer drug approvals in Europe had potential flaws.
GSK’s oral nicotine spray wins divided FDA panel’s backing despite abuse risks
With the federal spotlight on e-cigarette use, the FDA has grown increasingly wary of nicotine-based products with risks of abuse. That didn’t stop GlaxoSmithKline from winning a recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy. An...